Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 376Neoplasm Metastasis 21Neoplasms 11Advanced Breast Cancer 10Carcinoma, Intraductal, Noninfiltrating 8Triple Negative Breast Neoplasms 7Osteoporosis 7Carcinoma, Ductal, Breast 7Breast Neoplasms, Male 7Breast Diseases 7Breast Carcinoma In Situ 6Carcinoma, Lobular 5Prostatic Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Breast Cancer Metastatic 4Arthralgia 4Recurrence 3Ovarian Neoplasms 3Neoplasms, Hormone-Dependent 3Squamous Cell Carcinoma of Head and Neck 2Pain 2Obesity 2Neoplasms by Site 2Multiple Endocrine Neoplasia Type 1 2Infertility 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2HR Positive HER2 Negative Advanced Breast Cancer 2Estrogen Receptor-positive Breast Cancer 2Endometrial Neoplasms 2

Interventions

pembrolizumab 2Cyclophosphamide 2Cisplatin 2sargramostim 1regorafenib 1fludarabine 1entinostat 1durvalumab 1cemiplimab 1avelumab 1atezolizumab 1abemaciclib 1Surgical Procedures, Operative 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Platinum 1Pemetrexed 1Paclitaxel 1Nivolumab 1Midazolam 1Microarray Analysis 1Megestrol Acetate 1Levoleucovorin 1Leucovorin 1Letrozole 1LY3023414 1Interleukin-2 1Interferon-gamma 1Interferon-alpha 1Immunoenzyme Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Letrozole × Breast × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡